178 related articles for article (PubMed ID: 17123387)
1. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.
Berntorp E; Shapiro A; Astermark J; Blanchette VS; Collins PW; Dimichele D; Escuriola C; Hay CR; Hoots WK; Leissinger CA; Negrier C; Oldenburg J; Peerlinck K; Reding MT; Hart C
Haemophilia; 2006 Dec; 12 Suppl 6():1-7. PubMed ID: 17123387
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():37-41; discussion 41-2. PubMed ID: 17123392
[TBL] [Abstract][Full Text] [Related]
3. Immune tolerance: critical issues of factor dose, purity and treatment complications.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis in haemophilia patients with inhibitors.
Leissinger CA
Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
[TBL] [Abstract][Full Text] [Related]
5. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
[TBL] [Abstract][Full Text] [Related]
6. Application of current knowledge to the management of bleeding events during immune tolerance induction.
Di Paola J; Aledort L; Britton H; Carcao M; Grabowski E; Hutter J; Journeycake J; Kempton C; Leissinger C
Haemophilia; 2006 Nov; 12(6):591-7. PubMed ID: 17083508
[TBL] [Abstract][Full Text] [Related]
7. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
Dimichele D
Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
[TBL] [Abstract][Full Text] [Related]
8. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
[TBL] [Abstract][Full Text] [Related]
9. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.
Benson G; Auerswald G; Elezović I; Lambert T; Ljung R; Morfini M; Remor E; Salek SZ
Eur J Haematol; 2012 May; 88(5):371-9. PubMed ID: 22260405
[TBL] [Abstract][Full Text] [Related]
10. A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
Teitel J; Berntorp E; Dolan G; Fischer K; Gringeri A; Kessler C; Lambert T; Leissinger C; Nemes L; Shima M
Haemophilia; 2011 May; 17(3):516-21. PubMed ID: 21371181
[TBL] [Abstract][Full Text] [Related]
11. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
Mancuso ME; Graca L; Auerswald G; Santagostino E
Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
[TBL] [Abstract][Full Text] [Related]
12. International workshop on immune tolerance induction: consensus recommendations.
DiMichele DM; Hoots WK; Pipe SW; Rivard GE; Santagostino E
Haemophilia; 2007 Jul; 13 Suppl 1():1-22. PubMed ID: 17593277
[TBL] [Abstract][Full Text] [Related]
13. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
[TBL] [Abstract][Full Text] [Related]
14. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
15. Urgent inhibitor issues: targets for expanded research.
Hoots WK
Haemophilia; 2006 Dec; 12 Suppl 6():107-13. PubMed ID: 17123403
[TBL] [Abstract][Full Text] [Related]
16. Rituximab as a single agent in the management of adult patients with haemophilia A and inhibitors: marked reduction in inhibitor level and clinical improvement in bleeding but failure to eradicate the inhibitor.
Aleem A; Saidu A; Abdulkarim H; Al-Diab AR; Al-Sagheer A; Qayum A; Al-Momen AK
Haemophilia; 2009 Jan; 15(1):210-6. PubMed ID: 19149851
[TBL] [Abstract][Full Text] [Related]
17. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
Astermark J; Altisent C; Batorova A; Diniz MJ; Gringeri A; Holme PA; Karafoulidou A; Lopez-Fernández MF; Reipert BM; Rocino A; Schiavoni M; von Depka M; Windyga J; Fijnvandraat K;
Haemophilia; 2010 Sep; 16(5):747-66. PubMed ID: 20398077
[TBL] [Abstract][Full Text] [Related]
18. [Immune tolerance therapy for inhibitors in haemophilia A].
Oldenburg J
Hamostaseologie; 2008 Oct; 28 Suppl 1():S23-5. PubMed ID: 18958334
[TBL] [Abstract][Full Text] [Related]
19. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.
Gomperts ED
Haemophilia; 2006 Nov; 12(6):573-8. PubMed ID: 17083506
[TBL] [Abstract][Full Text] [Related]
20. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
